title: The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study.
abstract: OBJECTIVE
  To investigate the effectiveness of donepezil hydrochloride (Aricept) in treating persistent memory deficits in people with traumatic brain injury.
  
  
  METHODS
  Single subject ABAC design was used so that each participant could serve as their own control.
  
  
  METHODS
  Seven TBI survivors with persistent memory dysfunction, at least 1.5 years post-injury, underwent two 6-month trials of Aricept. The following tests were used to assess memory and cognition: Brief Visual Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test, Digit Span and Letter Number Sequence sub-test of the Wechsler Adult Intelligence Scale-III, Controlled Oral Word Association Test and Memory Functioning Questionnaire.
  
  
  METHODS
  During the first treatment phase, participants received 5 mg/day of Aricept for 1 month, increasing to 10 mg/day of Aricept for an additional 5 months. During the second treatment phase, participants received 5 mg/day of Aricept for the entire 6 months.
  
  
  RESULTS
  A repeated measures analysis of variance indicated significant improvement on immediate and delayed memory portions of the BVMT-R when taking 10 mg/day of Aricept.
  
  
  CONCLUSIONS
  Findings contribute to the growing body of research into the use of Aricept in treating memory deficits in TBI survivors and support the need for further research.
authors.affiliation: Craig Hospital, Englewood, Colorado 80110, USA. cmorey@craighospital.org
authors.forename: Clare E
authors.initials: CE
authors.lastname: Morey
authors.forename: Mark
authors.initials: M
authors.lastname: Cilo
authors.forename: James
authors.initials: J
authors.lastname: Berry
authors.forename: Chris
authors.initials: C
authors.lastname: Cusick
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001930:Brain Injuries / Q000150:complications*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D002908:Chronic Disease; D000077265:Donepezil; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D010865:Pilot Projects; D010880:Piperidines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil